Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07630077 | Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT07627321 | Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer(PRAD2) | not yet recruiting | Phase 2 | 39 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07622706 | Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07619911 | SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 84 | Fudan UniversityOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07618793 | Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | zhang yiOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07609251 | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） | not yet recruiting | Phase 2 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT07603661 | Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC | not yet recruiting | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07603791 | Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. | not yet recruiting | Phase 2 | 252 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 0 | May 22, 2026 | clinicaltrials |
| NCT07574684 | Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC(ALA /NSCLC) | not yet recruiting | Phase 2 | 60 | Ain Shams UniversityOTHER | 0 | May 8, 2026 | clinicaltrials |
| NCT07573696 | Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy | not yet recruiting | Phase 2 | 50 | Wen-zhao ZHONGOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT07247786 | Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)(MIGRANT) | not yet recruiting | Phase 2 | 68 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07567326 | Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC | not yet recruiting | Phase 2 | 78 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT07561983 | Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC(BEACON-Lung) | not yet recruiting | Phase 2 | 39 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07379398 | Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07554859 | GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 90 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07550920 | Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) | not yet recruiting | Phase 2 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07551414 | Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI | not yet recruiting | Phase 2 | 38 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07545213 | Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis | not yet recruiting | Phase 2 | 27 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07517640 | Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial | not yet recruiting | Phase 2 | 45 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06706219 | Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC | not yet recruiting | Phase 2 | 50 | Hunan Province Tumor HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07507188 | Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)(INSTAR) | not yet recruiting | Phase 2 | 80 | Yonsei UniversityOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT07500285 | Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II) | not yet recruiting | Phase 2 | 10 | Prof. Dr. Cemil Tascıoglu Education and Research Hospital OrganizationOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07438600 | Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC(TianjinCIH) | not yet recruiting | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07493980 | Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients | not yet recruiting | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07486648 | Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib(Precision) | not yet recruiting | Phase 1 / Phase 2 | 53 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07489703 | SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07001995 | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07418866 | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07413952 | Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07416058 | PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC(PHOENIX) | not yet recruiting | Phase 2 | 61 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07410611 | ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy | not yet recruiting | Phase 2 | 84 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07393555 | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) | not yet recruiting | Phase 2 | 117 | SWOG Cancer Research NetworkNETWORK | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07229339 | Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | not yet recruiting | Phase 1 / Phase 2 | 89 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07298148 | Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg | not yet recruiting | Phase 2 | 28 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07353476 | Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07343479 | Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases | not yet recruiting | Phase 2 | 45 | Zhejiang Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07294261 | Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC | not yet recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 253 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286942 | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial | not yet recruiting | Phase 2 | 24 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07281209 | A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07283198 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07274384 | Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial(HYPERBOLIC) | not yet recruiting | Phase 2 | 74 | Università Vita-Salute San RaffaeleOTHER | 0 | Dec 10, 2025 | clinicaltrials |
| NCT07271602 | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06882174 | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer(TIME-NSCLC) | not yet recruiting | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 0 | Dec 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2026source: clinicaltrials